Health-care companies fell as traders rotated out of defensive sectors back into the high-risk tech sector.
Novo Nordisk shares slipped after analysts at brokerage Deutsche Bank cut their rating on the Ozempic maker, warning that a recent deceleration in sales growth could continue. Intensified competition from Eli Lilly and smaller rivals has weighed on the Danish giant's earnings in recent quarters, as it gives up some of its early lead on the wildly popular GLP-1 category of drugs.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
August 27, 2026 17:41 ET (21:41 GMT)
